New data on Gilead’s remdesivir, released by accident, show no benefit for COVID-19

The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according a long-awaited clinical trial conducted in China. Stat